Skip to main content

By Biocat

Peptide vaccines are a new therapeutic approach to fight cancer and its importance as an alternative to treat cancer is growing in the recent years. To discuss the present and future of the subject, the Oncology Program at the Institute for Research in Biomedicine (IRB Barcelona), with the support of GP Pharm and BCN Peptides organizes the talk Novel multi-target multi-peptide vaccines for the treatment of cancer on 13th December in Barcelona. The expert invited is Dr. Harpreet Singh, currently Scientific Director of the german firm Immatics.

Immatics was established in 2000 and is dedicated to the identification of tumor antigens and the development of peptide vaccines against cancer. Particularly noteworthy are the three vaccines undergoing clinical studies: against renal cell carcinoma (stage III) colorectal cancer (stage I and II) and brain cancer (stage I). The company recently received the 2012 TiE50 Award (Recognizing World's Most Enterprisings Technology Startups).

IRB Barcelona, member of Oncocat Network, is working on several research programs and has a group specifically dedicated to the design, synthesis and structure of peptides and proteins. BCN Peptides focuses on the manufacturing of bioactive peptides for pharmaceutical and veterinary applications. On the other hand, GP Pharm is developing injectable products, some based on peptides, in the area of oncology and urology.


Inscription: free attendance

Date: 13 December 2012
Time: 4 pm
Venue: Barcelona Science Park (PCB) • Edifici Clúster • Sala Fèlix Serratosa • C/ Baldiri Reixach, 4-8 • Barcelona

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.